A detailed history of Wells Fargo & Company transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 17,009 shares of TBPH stock, worth $169,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,009
Previous 16,286 4.44%
Holding current value
$169,579
Previous $138,000 0.72%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.66 - $10.25 $5,538 - $7,410
723 Added 4.44%
17,009 $137,000
Q2 2024

Aug 13, 2024

SELL
$8.29 - $9.92 $12,965 - $15,514
-1,564 Reduced 8.76%
16,286 $138,000
Q1 2024

May 10, 2024

BUY
$8.22 - $11.59 $10,390 - $14,649
1,264 Added 7.62%
17,850 $160,000
Q4 2023

Feb 09, 2024

BUY
$8.58 - $11.4 $14,105 - $18,741
1,644 Added 11.0%
16,586 $186,000
Q3 2023

Nov 13, 2023

SELL
$8.38 - $10.44 $79,325 - $98,825
-9,466 Reduced 38.78%
14,942 $128,000
Q2 2023

Aug 15, 2023

BUY
$10.16 - $11.92 $111,028 - $130,261
10,928 Added 81.07%
24,408 $252,000
Q1 2023

May 12, 2023

BUY
$9.87 - $11.44 $122,950 - $142,508
12,457 Added 1217.69%
13,480 $146,000
Q4 2022

Feb 13, 2023

SELL
$9.65 - $11.34 $9,640 - $11,328
-999 Reduced 49.41%
1,023 $11,000
Q3 2022

Nov 14, 2022

SELL
$8.39 - $10.22 $4,908 - $5,978
-585 Reduced 22.44%
2,022 $21,000
Q2 2022

Aug 12, 2022

SELL
$8.41 - $10.34 $40,662 - $49,993
-4,835 Reduced 64.97%
2,607 $24,000
Q1 2022

May 16, 2022

SELL
$8.33 - $12.96 $188,774 - $293,699
-22,662 Reduced 75.28%
7,442 $71,000
Q4 2021

Feb 14, 2022

BUY
$7.42 - $11.05 $108,665 - $161,827
14,645 Added 94.73%
30,104 $334,000
Q3 2021

Nov 15, 2021

SELL
$6.77 - $14.41 $1.18 Million - $2.51 Million
-173,886 Reduced 91.84%
15,459 $114,000
Q2 2021

Aug 16, 2021

BUY
$14.52 - $22.46 $94,089 - $145,540
6,480 Added 3.54%
189,345 $2.75 Million
Q1 2021

May 13, 2021

SELL
$16.57 - $21.08 $1.48 Million - $1.88 Million
-89,297 Reduced 32.81%
182,865 $3.73 Million
Q4 2020

Feb 09, 2021

SELL
$14.89 - $20.16 $68,851 - $93,219
-4,624 Reduced 1.67%
272,162 $4.84 Million
Q3 2020

Nov 05, 2020

SELL
$14.79 - $22.49 $63,789 - $96,999
-4,313 Reduced 1.53%
276,786 $4.09 Million
Q2 2020

Aug 13, 2020

BUY
$20.64 - $30.69 $1.68 Million - $2.49 Million
81,190 Added 40.61%
281,099 $5.9 Million
Q1 2020

May 14, 2020

BUY
$17.84 - $31.21 $3.57 Million - $6.24 Million
199,909 New
199,909 $4.62 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $666M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.